我的
注册
会员中心
进入
帮助中心
联系我们
首页 > 药研快讯

Donanemab (LY3002813) dose-escalation study in Alzheimer's disease

Intravenous donanemab 10 mg/kg can reduce amyloid deposits in AD despite having a shorter than expected half-life.

发布时间:2021-02-14浏览数:657

Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association

Stage 1 is defined as the presence of β-cell autoimmunity as evidenced by the presence of two or more islet autoantibodies with normoglycemia and is presymptomatic, stage 2 as the …

发布时间:2015-12-01浏览数:456

1型糖尿病分期标准

1型糖尿病(T1DM)分期标准不仅为临床实践也为T1DM预防药物,如抗CD3抗体药物的开发提供了重要的理论依据。

发布时间:2015-12-01浏览数:561

A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer's disease mice

These studies have profound implications for the development of therapeutic Aβ antibodies for Alzheimer's disease.

发布时间:2012-01-06浏览数:645

Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques

A beta N3(pE) production and retention may play an early and critical role in senile plaque formation.

发布时间:1995-02-01浏览数:568

横切线®为注册商标

Copyright 2020 横切线®药研苑 备案号:粤ICP备18041379号-3